key: cord-0836982-0sc8mng9 authors: Bhopal, Sunil S.; Olabi, Bayanne; Bhopal, Raj title: Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes date: 2021-01-29 journal: Public Health DOI: 10.1016/j.puhe.2021.01.011 sha: 2c57e4d8d09963231630855df7dadbd45757f155 doc_id: 836982 cord_uid: 0sc8mng9 Public health professionals and clinicians are immersed in the ongoing and, in many countries, coming vaccination programmes for COVID-19. Published information from vaccine trials is complex. There are important and helpful insights about the nature of the available and forthcoming vaccines, immune responses and side-effects from phase II trials. We have systematically summarised information from 10 such trials on the nature of the vaccines, exclusions from the trials, immunological effects and side effects. Some important information within these trial reports is not available in the phase III trial papers, so a complete picture requires examination of phase II and phase III trials for each vaccine. We recommend our systematic approach for the examination of other upcoming COVID-19 vaccine phase II and III trials. The COVID-19 pandemic is having a serious impact on physical and mental health, the social order and economic development worldwide, with the long-term primary solution being population (herd) immunity through vaccination, with a contribution from natural infection particularly in children and young people for whom vaccines will not be available in the foreseeable future. 1 Governments, public health agencies, scientists and the media concur that a global return to normality will require the swift production and administration of safe and effective vaccines to willing and cooperative populations 2 3 . There are reasons for optimism, not least the speed with which scientific advance is occurring 4 with currently numerous vaccines being tested in phase I/II and a few phase III clinical trials. 5 There are over 200 individual trials registered to date 6 . Three vaccines, commonly known as the BioNTech-Pfizer, Moderna and AstraZeneca (Oxford) vaccines have gained emergency approvals based on phase III trials. Other vaccines have gained approval prior to phase III trials being published, with information not publicly available (e.g. The Indian Bharat Biontec vaccine 7 ). The extremely promising results of phase III trials are becoming available to health professionals or the public either in academic journals or regulatory agencies' websites. 8 Phase III trials are extremely complex and outside the scope of this paper, but results for the Moderna phase III, 9 Oxford 10 and Pfizer-BioNTech 11 trials have recently been published. We have synthesised the published results of phase II COVID-19 vaccine trials, including the nature of the vaccines, the design of the trial, exclusions, benefits relating to immunity and adverse events. In this paper we provide an overview in an easily accessible way to inform the public, healthcare workers, scientists and policymakers. In the supplementary file we provide simplified versions of the detailed tables in our preprint 12 . The phase II trials were based in the United Kingdom 13 given by intramuscular injection. Excepting the two mRNA vaccines from Pfizer, the vaccines underwent standard development methods (Box 1). The AstraZeneca trial was an exception in using another vaccine (meningococcal) as a control. All vaccines produced detectable neutralising antibodies, and T-cell responses were found where measured. 2) Viral vector vaccines 13 14 18 20 (genetically engineered virus to produce coronavirus proteins to generate an immune response) 3) RNA vaccines 19 Side effects were common but highly variable across vaccines, with few side effects reported for the Sinopharm and Sinovac vaccines (online Supplementary Table 2 and online Box 4). Publications rarely reported the duration of side effects but they were presumed to be mostly transient. The common symptoms in most vaccines included fatigue, muscle ache and fever and were more common in COVID-19 vaccine participants than controls, for example, as follows: In the largest, AstraZeneca, study 13 There were five reported serious adverse events, one of which was deemed to be vaccinerelated; this participant was hospitalised with fever because of suspicion of COVID-19 infection (Supplementary Table 2 ). Some serious adverse events have been reported in ongoing phase III trials, as discussed below. Given the importance of a COVID-19 vaccination for exiting pandemic restrictions, public health and clinical professionals across the world need to plan in advance of publication of phase III trials, not least because some vaccines are being implemented on the basis of phase II trials. However, only phase III and IV trials can provide important information on whether vaccination protects recipients from acquiring disease, or reduces the severity of acquired disease (especially death), and whether it prevents or reduces transmission. Definitive information is mainly on efficacy in reducing severity [9] [10] [11] . Phase II trials provide important additional insights to prepare. They indicate that an immune response is produced with all 10 vaccines considered, which provides optimism in relation to the numerous vaccines under development. Vaccine recipients need to know the range of side-effects and judge that these are Serious adverse effects seem to be rare. Even current Phase III studies are not likely to quantify accurately rare serious events and ongoing large pharmacovigilance studies will be required, particularly because even phase III trials were not conducted with the population who are being vaccinated first (older people, and those with co-morbidities). 27 In some vaccination strategies, including for influenza, children are vaccinated to increase herd (population) immunity, offering indirect protection for everyone. Presently, given these vaccines are not being tested in children under 18 years of age, it is unlikely to be recommended in this age group until appropriate child-specific research has been done 29 . Current plans in the United Kingdom are not to vaccinate the whole population, but to focus on those over 50-years of age and those providing healthcare, social care and frontline services. There are concerns that a COVID-19 vaccine could cause antibody-dependent enhancement on exposure to challenge or community-exposure to the virus 30 Our synthesis of phase II trials highlights some of the clinical and communication challenges that will need to be surmounted to allow widespread vaccination in 2021. These observations help inform researchers, public health specialists, policymakers and the public in relation to preparing for the forthcoming vaccination programmes. Finally, vaccine trials are being led from Europe, the United States, Australia and China so further trials will be needed in other contexts including Africa given the different age structure and impact of disease 32 . A multiplicity of vaccines will become available in 2021, but currently information from phase III trials has only been published for three vaccines, and is complex. Ten phase II publications provide insights for public health and clinical purposes that are complementary to phase III trials e.g. on the nature of these vaccines, exclusions from trials, their effects on immunity and side-effects. Phase II trials enrolled no one under 18 years and very few people over 80-years, and there were many reasons for exclusion. Vaccines of several types, some using novel methodologies, produce immune responses, indicating that there will be many other successful vaccines in the near future. Side-effects were mild or moderate but common, mimicking the symptoms of COVID-19, i.e. muscle ache, fatigue, fever and headache, posing challenges for clinicians in differentiating these adverse effects from COVID-19 illness and managing patients post-vaccination. Our approach to systematically tabulating information should now be applied to all trials. This is a task for an international agency like WHO. J o u r n a l P r e -p r o o f All authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. No additional or external funding underpinned the production of this manuscript. RB proposed this synthesis to systematise observations. SB and BO identified and synthesised the data. The sources of information and methods are described in our SSRN preprint 12 and briefly were searching Medline, MedRxiv and the ClinicalTrials.gov trial register up to 2 November 2020 to identify peer-reviewed publications and pre-print articles reporting results from ten phase II COVID19 vaccination trials (details in preprint). Essentially, we used database search techniques for academic papers and preprints to find phase II trials. Using the published preprint we simplified the material for this commentary and updated the text taking into account events up to 15 January 2021. COVID-19 zugzwang: Potential public health moves towards population (herd) immunity The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world When will a coronavirus vaccine be ready? Developing Covid-19 vaccines at pandemic speed SARS-CoV-2 vaccines in development Bharat Biotech's 'COVAXIN™' Emergency Use Authorization approval by DCGI-CDSCO, MoH&FW, a significant landmark in India's Scientific Discovery, and Scientists Capability Covid-19 vaccines: where are the data? Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Nature Of, Immune Reaction and Side Effects of COVID-19 Vaccines: Synthesis of Information from Ten Phase II Trials for Planning Vaccination Programmes. Immune Reaction and Side Effects of COVID-19 Vaccines: Synthesis of Information from Ten Phase II Trials for Planning Vaccination Programmes Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Diseases Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T-cell responses Children's mortality from COVID-19 compared with all-deaths and other relevant causes of death: epidemiological information for decision-making by parents, teachers, clinicians and policymakers Children and young people remain at low risk from COVID-19 mortality: updated time trends from USA COVID-19 deaths in children: comparison with all-and other causes and trends in incidence of mortality Population perspective comparing COVID-19 to all and common causes of death in seven European countries What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious Diseases Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination Herd immunity and vaccination of children for COVID-19 Informed consent disclosure to vaccine trial subjects of risk of COVID⁰19 vaccines worsening clinical disease Use of adenovirus type-5 vectored vaccines: a cautionary tale COVID-19 Global Mortality: Comparing Actual and Modelled Patterns in Space and Time Using an Infection Fatality Rate (IFR) Model